Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 13:9:1009021.
doi: 10.3389/fmed.2022.1009021. eCollection 2022.

The role of non-coding RNA in the diagnosis and treatment of Helicobacter pylori-related gastric cancer, with a focus on inflammation and immune response

Ao-Ran Liu  1 , Zi-Wei Yan  1 , Li-Yue Jiang  2 , Zhi Lv  1   3 , Yan-Ke Li  1   3 , Ben-Gang Wang  1   4
Affiliations
Review

The role of non-coding RNA in the diagnosis and treatment of Helicobacter pylori-related gastric cancer, with a focus on inflammation and immune response

Ao-Ran Liu et al. Front Med (Lausanne). .

Abstract

Helicobacter pylori (H. pylori) is one of the globally recognized causative factors of gastric cancer (GC). Currently, no definite therapy and drugs for H. pylori-related GC have been widely acknowledged although H. pylori infection could be eradicated in early stage. Inflammation and immune response are spontaneous essential stages during H. pylori infection. H pylori may mediate immune escape by affecting inflammation and immune response, leading to gastric carcinogenesis. As an important component of transcriptome, non-coding RNAs (ncRNAs) have been proven to play crucial roles in the genesis and development of H. pylori-induced GC. This review briefly described the effects of ncRNAs on H. pylori-related GC from the perspective of inflammation and immune response, as well as their association with inflammatory reaction and immune microenvironment. We aim to explore the potential of ncRNAs as markers for the early diagnosis, prognosis, and treatment of H. pylori-related GC. The ncRNAs involved in H. pylori-related GC may all hold promise as novel therapeutic targets for immunotherapy.

Keywords: H. pylori-related GC; Helicobacter pylori; immune response; inflammation; microRNA; non-coding RNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Microenvironment changes in H. pylori-infected gastric mucosa. The virulence factors of H. pylori can affect immune response or inflammation of host inducing H. pylori-related gastric carcinogenesis. The participation of H. pylori may not only directly through virulence factors but also by altering the expression of ncRNAs especially miRNAs, which might serve as potential therapeutic targets for H. pylori-related GC.
FIGURE 2
FIGURE 2
H. pylori infection alters the expression of ncRNAs leading to a series of biological effects in vivo and GC eventually.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. - PubMed
    1. Wang F, Meng W, Wang B, Qiao L. Helicobacter Pylori-induced gastric inflammation and gastric cancer. Cancer Lett. (2014) 345:196–202. - PubMed
    1. Crowe SE. Helicobacter pylori infection. N Engl J Med. (2019) 380:1158–65. - PubMed
    1. Bravo D, Hoare A, Soto C, Valenzuela MA, Quest AF. Helicobacter pylori in human health and disease: mechanisms for local gastric and systemic effects. World J Gastroenterol. (2018) 24:3071–89. 10.3748/wjg.v24.i28.3071 - DOI - PMC - PubMed
    1. Diaz P, Valenzuela Valderrama M, Bravo J, Quest AFG. Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression. Front Microbiol. (2018) 9:5. 10.3389/fmicb.2018.00005 - DOI - PMC - PubMed